Similar articles for PMID: 25327540

Year	Number of Results
1985	1
1998	1
2000	1
2002	3
2004	1
2005	5
2006	5
2007	5
2008	11
2009	12
2010	10
2011	14
2012	14
2013	14
2014	16
2015	19
2016	26
2017	19
2018	17
2019	16
2020	12
2021	9
2022	13
2023	3
2024	0

1

Pharmacological characterization of ZYDPLA1, a novel long-acting dipeptidyl peptidase-4 inhibitor.

Jain MR, Joharapurkar AA, Bahekar RH, Patel H, Jadav P, Kshirsagar SG, Patel VJ, Patel KN, Ramanathan VK, Patel PR, Desai RC. Jain MR, et al. J Diabetes. 2015 Sep;7(5):708-17. doi: 10.1111/1753-0407.12233. Epub 2014 Dec 17. J Diabetes. 2015. PMID: 25327540

2

ZY15557, a novel, long acting inhibitor of dipeptidyl peptidase-4, for the treatment of Type 2 diabetes mellitus.

Jain MR, Joharapurkar AA, Kshirsagar SG, Patel VJ, Bahekar RH, Patel HV, Jadav PA, Patel PR, Desai RC. Jain MR, et al. Br J Pharmacol. 2017 Jul;174(14):2346-2357. doi: 10.1111/bph.13842. Epub 2017 Jun 13. Br J Pharmacol. 2017. PMID: 28452143 Free PMC article.

3

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.

Lee B, Shi L, Kassel DB, Asakawa T, Takeuchi K, Christopher RJ. Lee B, et al. Eur J Pharmacol. 2008 Jul 28;589(1-3):306-14. doi: 10.1016/j.ejphar.2008.04.047. Epub 2008 Apr 26. Eur J Pharmacol. 2008. PMID: 18538760

4

Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.

Kim SH, Jung E, Yoon MK, Kwon OH, Hwang DM, Kim DW, Kim J, Lee SM, Yim HJ. Kim SH, et al. Eur J Pharmacol. 2016 Oct 5;788:54-64. doi: 10.1016/j.ejphar.2016.06.016. Epub 2016 Jun 11. Eur J Pharmacol. 2016. PMID: 27298192

5

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.

Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC. Patel H, et al. Drug Res (Stuttg). 2017 Apr;67(4):223-227. doi: 10.1055/s-0042-122776. Epub 2017 Feb 3. Drug Res (Stuttg). 2017. PMID: 28158894

6

RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.

Singh S, Roy S, Sethi S, Benjamin B, Sundaram S, Khanna V, Kandalkar SR, Pal C, Kant R, Patra AK, Rayasam G, Mittra S, Saini KS, Paliwal J, Chugh A, Ahmed S, Sattigeri J, Cliff I, Ray A, Bansal VS, Bhatnagar PK, Davis JA. Singh S, et al. Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Epub 2010 Jun 9. Eur J Pharmacol. 2011. PMID: 20540938

7

(2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.

Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S. Tajima A, et al. Eur J Pharmacol. 2011 Mar 25;655(1-3):99-107. doi: 10.1016/j.ejphar.2011.01.010. Epub 2011 Jan 22. Eur J Pharmacol. 2011. PMID: 21262219

8

A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.

Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S. Fukuda-Tsuru S, et al. Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. doi: 10.1016/j.ejphar.2012.09.024. Epub 2012 Sep 26. Eur J Pharmacol. 2012. PMID: 23022337

9

7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.

Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I. Yamazaki K, et al. J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. doi: 10.1124/jpet.106.112805. Epub 2006 Sep 15. J Pharmacol Exp Ther. 2006. PMID: 16980568

10

Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

214 results

Results by year